{
"id":"mk19_b_gm_t52",
"number":52,
"bookId":"gm2",
"title":{
"__html":"Initiating Systemic Hormone Therapy for Vasomotor Symptoms in Women Younger Than 60 Years or Within 10 Years of Menopause Onset<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f1fb8b",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 52. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t52"
}
]
},
"Initiating Systemic Hormone Therapy for Vasomotor Symptoms in Women Younger Than 60 Years or Within 10 Years of Menopause Onset",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ef1da",
"class":"cell txt l",
"children":[
"Step 1: Confirm that hot flashes/night sweats are moderate to severe in intensity and are refractory to lifestyle modifications."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9625da",
"class":"cell txt l",
"children":[
"Step 2: Assess for contraindications to systemic hormone therapy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c2678",
"class":"cell txt l",
"children":[
"Step 3: Assess the patient's baseline risk for CVD, VTE, and breast cancer. For women at increased risk, consider nonhormonal treatments.",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b0dcf",
"class":"cell txt l",
"children":[
"Step 4: Use the lowest dose of estrogen that relieves menopausal symptoms."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86b6c1",
"class":"cell txt l",
"children":[
"Step 5: Add systemic progesterone therapy to estrogen therapy in women who have an intact uterus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d93396",
"class":"cell txt l",
"children":[
"Step 6: Assess symptoms and side effects after initiating therapy and adjust the dose of estrogen if symptoms are persistent."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b9573",
"class":"cell txt l",
"children":[
"Step 7: Reassess symptoms and risk factors for CVD, VTE, and breast cancer annually."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd48c7",
"class":"cell txt l",
"children":[
"Step 8: Discontinue systemic hormone therapy if the risks of treatment outweigh the benefits."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CVD = cardiovascular disease; VTE = venous thromboembolism"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"According to the 2017 hormone therapy position statement of the North American Menopause Society, the safety profile of hormone therapy in women who initiate therapy more than 10 years after menopause onset or at age 60 years or older is not as favorable as for younger women, owing to greater absolute risks for CVD, VTE, and breast cancer."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Endocrine Society guidelines recommend that women at high risk for CVD, VTE, or breast cancer consider nonhormonal therapies. For women at moderate risk for CVD or VTE who still desire hormone therapy, transdermal estrogen, which has less risk versus oral preparations of estrogen, should be considered."
]
]
}